Today: 22 November 2025
Subscribe
Browse Category

Healthcare Investments News 1 November 2025 - 19 November 2025

Boston Scientific Stock Rockets on Blowout Q3 Results and Major Medical Wins

Boston Scientific (BSX) Stock Today: Price Slips as Neuromodulation Bull Case, Epic EHR Deal and Big Fund Moves Shape the Outlook – November 19, 2025

Boston Scientific Corporation (NYSE: BSX) shares traded lower on Wednesday, November 19, 2025, even as a wave of fresh research, strategic partnership news and institutional ownership updates painted a largely constructive long‑term picture for the medtech giant. BSX stock price on 19 November 2025 As of late Wednesday trading, Boston Scientific stock was changing hands at around $96.6, down roughly 2.6% on the day. Intraday, BSX has traded in a range of roughly $96–$100, with volume running in the high single‑digit millions of shares. Investing.com Recent price action shows a short losing streak: BSX closed at about $99.2 on Tuesday
19 November 2025
 ·  ·  ·  ·  · 
Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Today, November 13, 2025: BioNTech Stake Sale, Metsera Deal and a 6%+ Dividend Put PFE Back in Focus

Pfizer stock (NYSE: PFE) is trading higher today as investors digest a fresh batch of headlines: a planned sale of the company’s remaining stake in Covid-19 vaccine partner BioNTech, ongoing reaction to its $10 billion Metsera obesity-drug deal, and renewed debate around whether PFE’s rich dividend compensates for its strategic risks. As of the latest quotes on Thursday, November 13, Pfizer shares are changing hands around $25.9, up roughly 1.4% on the day after trading between about $25.3 and $25.9 in today’s session. That puts the company’s market capitalization near $147 billion, with the stock still trading on a single-digit earnings multiple and yielding around 6.6–7% on a
13 November 2025
 ·  ·  ·  ·  ·  · 
Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Technical Analysis – Levels to Watch From a technical perspective, Pfizer’s stock has been basing in the low-to-mid $20s and has yet to break out of its longer-term downtrend. The 52-week range is roughly $20.92 to $30.43 ts2.tech, and the late-September rally stalled out near the upper-$20s – a zone that now acts as an overhead resistance (around $26–$27). Notably, PFE is trading below its 200-day moving average (~$27), indicating lingering bearish momentum trefis.com. On the upside, a decisive push above the $27–$28 level (and the 200-day MA) would be a bullish signal that the stock’s trend is turning. In
1 November 2025
 ·  ·  ·  ·  · 
Go toTop